Paul Pickrell
Rheumatology · Austin, TXNPI 1114935418
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 483 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Amgen at 32.3% of the total.
Across 483 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Pfizer$508
- GSK$366
- Lilly USA, LLC$362
- Boehringer Ingelheim$338
- plus $1K from 15 others
Across 8,409 payments — averaging $4869.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$21.8M
- Pfizer$5.8M
- AstraZeneca$4.3M
- AbbVie$1.5M
- Astrazeneca UK Limited$1.4M
- Emergent Biosolutions Inc.$1.2M
- plus $5M from 20 others
What the payments were for
- Food & beverage$7,82999%
- Education$551%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 153 | $2,553 |
| AbbVie | 157 | $2,350 |
| Pfizer | 40 | $508 |
| GSK | 22 | $366 |
| Lilly USA, LLC | 23 | $362 |
| Boehringer Ingelheim | 15 | $338 |
| AstraZeneca | 8 | $220 |
| Aurinia Pharma U.S., Inc. | 6 | $161 |
| Sanofi | 8 | $147 |
| E.r. Squibb & Sons, L.L.C. | 6 | $142 |
| Radius Health, Inc. | 8 | $137 |
| Bristol Myers Squibb | 12 | $117 |
| Johnson & Johnson | 3 | $95 |
| UCB, Inc. | 4 | $94 |
| Genentech USA, Inc. | 4 | $79 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| Novartis | 4 | $59 |
| Collegium Pharmaceutical, Inc. | 3 | $46 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,904 in reported general payments places this provider in the 60th percentile of 512 rheumatology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmbienZolpidem Tartrate | 12 | $7,452 |
| Ambien CrZolpidem Tartrate | 12 | $7,452 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 87 | $3,766 |
| Hydroxychloroquine Sulfate | 69 | $2,442 |
| Oxycodone Hcl | 58 | $2,348 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 30 | $950 |
| MethotrexateMethotrexate Sodium | 64 | $864 |
| Prednisone | 60 | $415 |
| Zolpidem Tartrate | 48 | $293 |
| Gabapentin | 42 | $292 |
| Tizanidine Hcl | 24 | $203 |
| Diazepam | 14 | $71 |
| Alprazolam | 15 | $63 |
| ConstuloseLactulose | 17 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCAmbien | $75 | $7,45212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Austin
- Robert KovalAustin$150K
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.